[Complete response of advanced rectal cancer with combined therapy of S-1 + chemo-radiation plus FOLFIRI--a case report].
A 64-year-old man was admitted to general practitioner because of dyschezia. He was diagnosed with lower rectal cancer by colonoscopy and referred to our hospital for therapy. At first, in spite of multiple liver metastases, we tried a resection of primary lesion in order to control of breeding, dyschezia and pain. However, we had to give up the resection, so we made sigmoid colostomy only. One month after the operation, a combination chemo-radiotherapy using S-1 was performed for controlling of local symptom. S-1 (120 mg/day) was administered on days 1-14, and 21-35. Radiation (2 Gy) was administered on days 1-5, 7-12, 14-19, 21-26, 28-33, and 35-40, a total of 60 Gy. One month after this therapy, the tumor was remarkably reduced and the reduction was judged as partial response. Moreover after 6 courses of FOLFIRI, the reduction was judged as complete response. Local control therapy (S-1+chemo-radiation) plus systemic therapy (FOLFIRI) is one of the promising effective therapies for advanced rectal cancer.
Hata
Taishi
T
Dept. of Surgery, Toyonaka Municipal Hospital.
Kagawa
Yoshinori
Y
Ikeda
Kimimasa
K
Kato
Hiroaki
H
Takamoto
Kaori
K
Oshima
Noriko
N
Maeda
Sakae
S
Nomura
Motonari
M
Hayashi
Shouho
S
Sasaki
Takashi
T
Shimizu
Junzo
J
Kawanishi
Kensyu
K
Fujita
Junya
J
Akagi
Kenzo
K
Tsukahara
Yasuo
Y
Kitada
Masashi
M
Shimano
Takashi
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004338:Drug Combinations; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D011351:Proctoscopy; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D012074:Remission Induction; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D014408:Biomarkers, Tumor; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin